Skip to content

Here’s how much a $10k investment in Pfizer stock 5 years ago is now worth

Here’s how much a $10k investment in Pfizer stock 5 years ago is now worth

For Pfizer (NYSE: PFE) investors, 2023 has been a tumultuous journey, marked by a nearly 50% decline in the stock – making it the drugmaker’s worst-performing year on record

The substantial drop is primarily attributed to a sharp decrease in demand for Pfizer’s once-thriving Covid-19 products, leading to a rapid decline in sales and prompting investors to abandon ship. 

Historically regarded as a low-risk investment, the abrupt downturn has left long-term PFE investors grappling with losses.

Investors PFE stakes at loss after a poor 2023

As mentioned earlier, 2023 is the worst-known year for Pfizer in terms of its stock market performance. Earlier this week, PFE crumbled to a 10-year low after the company issued a worse-than-anticipated forecast for its fiscal 2024 year.

According to chart provider Barchart, an investment of $10,000 in PFE shares five years ago would be worth $7.766 today, including dividends. That represents a return on investment (ROI) of -22%.

“Not bad!” Barchart sarcastically commented on this return in its December 15 post. 

This marks a significant blow for investors, particularly institutions that have multi-million-dollar stakes in the company. As one of the largest pharmaceutical companies globally, Pfizer has often been viewed as a stable and established player in the healthcare sector. 

That trend was disrupted this year after the company started reporting substantial losses and facing significant revenue declines due to weak sales of its coronavirus-related products including Comirnaty, Paxlovid, and vaccines. 

At the time of publication, shares of PFE were sitting at $26.13, a new more than a decade low after slipping 2% on Thursday.

PFE 1-day price chart. Source: Finbold


Over the past month, the stock tumbled over 13.4%, and more than 49% since the beginning of 2023.

Capital Group, one of the major stakeholders in Pfizer, sold an additional 13% of their PFE stake last quarter, amounting to more than 32 million shares. The move comes after the investment firm offloaded 20% of its position during the June quarter. 

Buy stocks now with Interactive Brokers – the most advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.